Somewhat Positive Press Coverage Somewhat Unlikely to Affect Assembly Biosciences (ASMB) Stock Price

Headlines about Assembly Biosciences (NASDAQ:ASMB) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Assembly Biosciences earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.9872499739611 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Several analysts have recently weighed in on ASMB shares. BidaskClub upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Chardan Capital started coverage on shares of Assembly Biosciences in a research report on Tuesday, May 30th. They set a “buy” rating and a $35.00 target price on the stock. Finally, Zacks Investment Research lowered shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Monday, August 14th.

Shares of Assembly Biosciences (ASMB) traded up 0.32% during mid-day trading on Tuesday, hitting $28.08. 18,333 shares of the stock traded hands. The firm’s market capitalization is $487.58 million. The company’s 50 day moving average is $24.63 and its 200 day moving average is $23.67. Assembly Biosciences has a one year low of $6.61 and a one year high of $28.73.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/09/12/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-assembly-biosciences-asmb-stock-price.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Insider Buying and Selling by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply